Products
Data
Feature
Plans
Request Demo
Sign Up for Free
Blog
Valuable Targets
Advanced Tech.
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
PTPRA Biologics Sequence Review Report 2026: Receptor-type tyrosine-protein phosphatase alpha Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of PTPRA protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
CD36 Biologics Sequence Review Report 2026: Platelet glycoprotein 4 Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of CD36 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
CD3G Biologics Sequence Review Report 2026: T-cell surface glycoprotein CD3 gamma chain Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of CD3G protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
FCGR3A Biologics Sequence Review Report 2026: Low affinity immunoglobulin gamma Fc region receptor III-A Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of FCGR3A protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
CD55 Biologics Sequence Review Report 2026: Complement decay-accelerating factor Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of CD55 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
CD69 Biologics Sequence Review Report 2026: Early activation antigen CD69 Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of CD69 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
ITGA1 Biologics Sequence Review Report 2026: Integrin alpha-1 Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of ITGA1 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
8 min read
ITGA8 Biologics Sequence Review Report 2026: Integrin alpha-8 Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of ITGA8 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
8 min read
CD96 Biologics Sequence Review Report 2026: T-cell surface protein tactile Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of CD96 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
ITGAE Biologics Sequence Review Report 2026: Integrin alpha-E Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of ITGAE protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
ITGB8 Biologics Sequence Review Report 2026: Integrin beta-8 Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of ITGB8 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
ITGB7 Biologics Sequence Review Report 2026: Integrin beta-7 Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of ITGB7 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
<
1
<<
190
191
192
193
194
>>
1503
>